Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis.

MLA

Vilskersts, Reinis, et al. “Methyl-γ-Butyrobetaine Decreases Levels of Acylcarnitines and Attenuates the Development of Atherosclerosis.” Vascular Pharmacology, vol. 72, Sept. 2015, pp. 101–07. EBSCOhost, https://doi.org/10.1016/j.vph.2015.05.005.

APA

Vilskersts, R., Kuka, J., Liepinsh, E., Makrecka-Kuka, M., Volska, K., Makarova, E., Sevostjanovs, E., Cirule, H., Grinberga, S., & Dambrova, M. (2015). Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis. Vascular Pharmacology, 72, 101–107. https://doi.org/10.1016/j.vph.2015.05.005

Chicago

Vilskersts, Reinis, Janis Kuka, Edgars Liepinsh, Marina Makrecka-Kuka, Kristine Volska, Elina Makarova, Eduards Sevostjanovs, Helena Cirule, Solveiga Grinberga, and Maija Dambrova. 2015. “Methyl-γ-Butyrobetaine Decreases Levels of Acylcarnitines and Attenuates the Development of Atherosclerosis.” Vascular Pharmacology 72 (September): 101–7. doi:10.1016/j.vph.2015.05.005.